Wells Fargo & Company Immunity Bio, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 106,271 shares of IBRX stock, worth $541,982. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,271
Previous 102,475
3.7%
Holding current value
$541,982
Previous $647,000
39.1%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IBRX
# of Institutions
205Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$86.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$58.3 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$44.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$19.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$11.5 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.04B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...